Moncef Slaoui

Latest Headlines

Latest Headlines

Don't split up the dynamic duo of GSK's vaccines and drugs, vax chief says

Prominent U.K. investor Neil Woodford has been calling for a four-way breakup of GlaxoSmithKline, a company he says is too "complicated" for its own good. But take it from GSK vaccines chief Moncef Slaoui--splitting apart is a bad idea, at least on the vaccines front.

Science pays: 2013's 10 best-compensated R&D chiefs in biopharma

For an idea of what kind of year a drug developer had, take a look at what it paid its head of R&D. Click through our roundup for a look at who ranks where in the biopharma R&D world. Read more >>

Top 15 highest paid biopharma R&D chiefs

Being an R&D chief at a major biopharma company in today's environment of major research cutbacks, patent expirations and pressure from investors to speed new drugs to market is no easy...

Merck to invest in Canadian VC fund

It takes money to make money and yet another pharmaceutical maker is partnering in a venture capital fund, this one designed to draw drug companies to Quebec.

GSK, J&J back Index's new $200M fund for early-stage deals

GlaxoSmithKline and Johnson & Johnson are teaming up with Index Ventures to launch a $200 million fund devoted exclusively to backing early-stage biotechs

GSK studies Chinese remedies to discover new drugs

Amid GlaxoSmithKline's ($GSK) major push to expand in China, the London-based drugmaker has located a new R&D unit in that country that will investigate traditional Chinese medicines. The move is

GSK's Slaoui opts for more flexible approach in DPU change-up

Now that GlaxoSmithKline ($GSK) has hit the three-year mark on its closely watched experiment with Drug Performance Units, R&D Chairman Moncef Slaoui (pictured) tells FierceBiotech the pharma

GSK will cut 3 R&D units, add 4 as DPU review triggers shakeup

Following a three-year review of its new approach to R&D, GlaxoSmithKline ($GSK) today revealed that it has decided to ax three of its 38 tightly-focused research units and add four more in a

GSK readies its much-anticipated 3-year review for DPUs

In one of the most anticipated R&D events of the year, GlaxoSmithKline ($GSK) execs are readying a summary judgment on the results of the first three-year round of results for their

GSK's new R&D culture forces research chiefs to hustle for support

Of all the Big Pharmas anxiously attempting to reinvent the way they discover and develop new drugs, few if any have been as ambitious about creating a new R&D culture as GlaxoSmithKline ($GSK).